Latest Articles

This article examines how next-generation sequencing and state-of-the-art imaging technologies are being combined to characterize and map the spatial organization of cell types in tissues.

Researchers investigated the ability of metformin to protect human cells and mice from DNA damage due to radiation exposure. If successfully repurposed, the drug has the potential to help at-risk groups, such as cancer patients and astronauts.

We spoke to physician–scientist Professor Pradipta Ghosh about what drove her to follow this career path, her current work, the value of and challenges faced by physician–scientists and advice for those who are considering following in her footsteps.

In this interview, we spoke to Dr. Raquel Cuella Martin to learn about her research, her experiences working as an LGBTQIA+ researcher in STEMM and her advice for others beginning a STEMM career.

Dr. Emma Slack, Science Writer at ME Research UK, updates Technology Networks on the latest research advancements regarding myalgic encephalomyelitis/chronic fatigue syndrome.

Professor Giles Oldroyd is one of the few openly queer scientists who have been inducted into both the prestigious Royal Society (UK) and the National Academy of Sciences (USA). In this interview, he speaks candidly about his experiences in STEMM.

Technology Networks spoke to Dr. Steven Benner to learn more about what synthetic "alien" DNA can tell us about life on other planets and how this technology could be harnessed to improve disease diagnostics and treatment.

CRISPR gene editing has enabled scientists to rewrite the genetic code of living organisms and is revolutionizing medicine. Here, we highlight some of the latest applications of CRISPR gene editing in infectious disease research.

In this interview, Alex Freeman, the founder of Octopus, discusses the progress made since the platform's launch and the ongoing challenges of establishing a new paradigm in academic publishing.

Scientists have taken a fresh approach to finding a way to target neuroblastoma, the most common solid tumor of infancy. Their novel gene target could offer hope for finding alternative treatments with fewer long-term side effects.